All the news articles and press releases in one place.

Date / Time Source Company Sector Market Cap Announcement
29Jan20 06:00 GNW Novartis AG Health 208,186m Novartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019
06Jan20 06:00 GNW Novartis AG Health 208,186m Novartis completes tender offer for all outstanding shares of The Medicines Company
16Dec19 06:15 GNW Novartis AG Health 208,186m Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma
05Dec19 06:00 GNW Novartis AG Health 208,186m Novartis tender offer for The Medicines Company commences
24Nov19 20:00 GNW Novartis AG Health 208,186m Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death
15Nov19 20:06 GNW Novartis AG Health 208,186m New Novartis medicine Adakveo® (crizanlizumab) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease
01Nov19 06:15 GNW Novartis AG Health 208,186m Novartis Cosentyx® shows encouraging results versus Humira®* from first-of-its-kind head-to-head trial in psoriatic arthritis
30Oct19 06:00 GNW Novartis AG Health 208,186m Novartis announces AVXS-101 intrathecal study update
22Oct19 06:00 GNW Novartis AG Health 208,186m Novartis delivered another strong quarter with double digit sales growth and core1 margin expansion; 2019 sales and profit guidance raised; Beovu launched in US
08Oct19 06:15 GNW Novartis AG Health 208,186m Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
02Oct19 06:15 GNW Novartis AG Health 208,186m Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum
29Sep19 15:30 GNW Novartis AG Health 208,186m Novartis Kisqali® delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients
17Sep19 06:15 GNW Novartis AG Health 208,186m Novartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis
30Aug19 06:15 GNW Novartis AG Health 208,186m Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies
29Jul19 06:00 GNW Novartis AG Health 208,186m Novartis provides update on Phase III PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFpEF)
18Jul19 06:00 GNW Novartis AG Health 208,186m Novartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increased
01Jul19 16:30 GNW Novartis AG Health 208,186m Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio
07Jun19 06:00 GNW Novartis AG Health 208,186m Novartis announces new leader of Pharmaceuticals Business Unit
26May19 23:00 GNW Novartis AG Health 208,186m FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
24May19 17:41 GNW Novartis AG Health 208,186m AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families
24May19 17:32 GNW Novartis AG Health 208,186m AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)
08May19 23:20 GNW Novartis AG Health 208,186m Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care
24Apr19 06:00 GNW Novartis AG Health 208,186m Novartis starts 2019 with strong sales and double digit core[1] operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgraded
26Mar19 23:35 GNW Novartis AG Health 208,186m Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
22Mar19 06:00 GNW Novartis AG Health 208,186m Novartis plans for Alcon spin-off on April 9, 2019
14Mar19 06:15 GNW Novartis AG Health 208,186m Novartis announces change in Sandoz leadership
25Feb19 22:55 GNW Novartis AG Health 208,186m Novartis issues summary financial information for the Alcon eye care business ahead of shareholder vote on proposed spin-off
30Jan19 15:17 GNW Novartis AG Health 208,186m NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2018
30Jan19 06:00 GNW Novartis AG Health 208,186m Novartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018
21Dec18 13:53 GNW Novartis AG Health 208,186m Novartis successfully completes acquisition of Endocyte
20Dec18 06:00 GNW Novartis AG Health 208,186m Novartis announces new CEO of Oncology Business Unit
10Dec18 20:42 GNW Novartis AG Health 208,186m Sandoz Inc. and Pear Therapeutics Obtain FDA Clearance for reSET-O(TM) to Treat Opioid Use Disorder
08Dec18 13:00 GNW Novartis AG Health 208,186m Novartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease
06Dec18 15:30 GNW Novartis AG Health 208,186m Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses
03Dec18 06:15 GNW Novartis AG Health 208,186m Novartis announces FDA filing acceptance and Priority Review of AVXS-101, a one-time treatment designed to address the genetic root cause of SMA Type 1
02Dec18 15:15 GNW Novartis AG Health 208,186m Real-world data show Novartis drug Revolade® improves outcomes for ITP patients compared to other second-line therapies
01Dec18 19:30 GNW Novartis AG Health 208,186m Novartis announces longer-term analyses from pivotal Kymriah® trials that showed durable responses are maintained in patients with advanced blood cancers
01Dec18 15:15 GNW Novartis AG Health 208,186m Novartis announces new crizanlizumab (SEG101) data analysis in sickle cell disease, and investment in SENTRY clinical program
29Nov18 06:15 GNW Novartis AG Health 208,186m Novartis announces EU approval of Gilenya® for children and adolescents with MS, making it the first and only oral disease-modifying treatment for these patients in Europe
27Nov18 06:15 GNW Novartis AG Health 208,186m Sandoz receives eighth European Commission approval for a biosimilar with Ziextenzo® (pegfilgrastim)
27Nov18 06:00 GNW Novartis AG Health 208,186m Alcon to highlight its vision, strategy and benefits as a standalone company to investors and analysts in New York and London
23Nov18 06:15 GNW Novartis AG Health 208,186m Novartis announces landmark EU approval for one-time gene therapy Luxturna® to restore vision in people with rare inherited retinal disease
20Nov18 13:15 GNW Novartis AG Health 208,186m Novartis rises to second place in 2018 Access to Medicine Index
16Nov18 21:30 GNW Novartis AG Health 208,186m FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication
16Nov18 13:09 GNW Novartis AG Health 208,186m Novartis receives positive CHMP opinion to expand Kisqali® combination therapy to all women with HR+/HER2- locally advanced or metastatic breast cancer
13Nov18 21:29 GNW Novartis AG Health 208,186m Alcon files initial Form 20-F registration statement with SEC for proposed spinoff; plans investor days in New York and London
13Nov18 21:28 GNW Novartis AG Health 208,186m Alcon files initial Form 20-F registration statement with SEC for proposed spinoff; plans investor days in New York and London
11Nov18 16:45 GNW Novartis AG Health 208,186m New Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients
05Nov18 06:00 GNW Novartis AG Health 208,186m Novartis R&D update highlights industry leading development pipeline including potential blockbusters and advanced therapy platforms
02Nov18 22:00 GNW Novartis AG Health 208,186m Sandoz decides not to pursue US biosimilar rituximab; will focus on robust biosimilar portfolio for unmet access and sustainability needs
02Nov18 21:15 GNW Novartis AG Health 208,186m Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology
31Oct18 16:30 GNW Novartis AG Health 208,186m Sandoz receives US FDA approval for biosimilar Hyrimoz(TM) (adalimumab-adaz)
29Oct18 06:15 GNW Novartis AG Health 208,186m Novartis announces clinical collaboration with Pfizer to advance the treatment of NASH
27Oct18 15:08 GNW Novartis AG Health 208,186m Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD
26Oct18 06:15 GNW Novartis AG Health 208,186m Novartis receives approval for Cosentyx® label update in Europe to include dosing flexibility in psoriatic arthritis
23Oct18 06:15 GNW Novartis AG Health 208,186m Alcon to develop SMART Suite digital health platform for cataract surgery
22Oct18 23:30 GNW Novartis AG Health 208,186m Novartis announces Lancet publication of pioneering study in migraine prevention showing efficacy of Aimovig® where other treatments have failed
22Oct18 08:15 GNW Novartis AG Health 208,186m Novartis COMBI-AD study of Tafinlar® + Mekinist® continues to demonstrate relapse free survival benefit in patients with BRAF V600-mutant stage III melanoma
20Oct18 15:30 GNW Novartis AG Health 208,186m Novartis investigational BYL719 (alpelisib) plus fulvestrant nearly doubles median PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer compared to fulvestrant alone
19Oct18 15:00 GNW Novartis AG Health 208,186m Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC
19Oct18 06:15 GNW Novartis AG Health 208,186m Novartis announces presentation of new Lutathera® NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden
18Oct18 06:02 GNW Novartis AG Health 208,186m Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms
18Oct18 06:02 GNW Novartis AG Health 208,186m Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms
18Oct18 06:00 GNW Novartis AG Health 208,186m Novartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth
18Oct18 06:00 GNW Novartis AG Health 208,186m Novartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth
16Oct18 06:15 GNW Novartis AG Health 208,186m Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx® leadership in spondyloarthritis
11Oct18 21:35 GNW Novartis AG Health 208,186m Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access
10Oct18 21:30 GNW Novartis AG Health 208,186m Novartis announces new data from the first direct head-to-head trial to demonstrate superior efficacy of Gilenya® over Copaxone® in patients with relapsing remitting multiple sclerosis
10Oct18 06:15 GNW Novartis AG Health 208,186m Breadth of data at ECTRIMS underpins Novartis' relentless commitment to decoding the science of multiple sclerosis (MS) and decreasing the patient burden
09Oct18 21:30 GNW Novartis AG Health 208,186m Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study
08Oct18 06:15 GNW Novartis AG Health 208,186m Novartis announces FDA and EMA filing acceptance of siponimod, the first and only drug shown to meaningfully delay disability progression in typical SPMS patients
04Oct18 06:15 GNW Novartis AG Health 208,186m Sandoz Healthcare Access Challenge (HACk) returns, seeking digital solutions to local healthcare access challenges
03Oct18 06:15 GNW Novartis AG Health 208,186m Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals
22Sep18 13:41 GNW Novartis AG Health 208,186m Novartis to file for new Lucentis® (ranibizumab) indication in retinopathy of prematurity (ROP), a rare disease in premature infants that often leads to blindness
22Sep18 13:36 GNW Novartis AG Health 208,186m New analysis of Novartis Phase III brolucizumab (RTH258) data reinforces superior reduction of retinal fluid, a key marker of disease activity in nAMD
21Sep18 12:27 GNW Novartis AG Health 208,186m Sandoz receives positive CHMP opinion for proposed biosimilar pegfilgrastim
21Sep18 12:25 GNW Novartis AG Health 208,186m Novartis receives positive CHMP opinion for Gilenya® for the treatment of children and adolescents with MS, marking a major medical advance for young MS patients in Europe
21Sep18 12:24 GNW Novartis AG Health 208,186m Novartis announces positive CHMP opinion for one-time gene therapy Luxturna® to treat children and adults with rare inherited retinal disease
17Sep18 21:30 GNW Novartis AG Health 208,186m World's largest Alzheimer's survey reveals most adults believe a cure will be developed in their lifetime
17Sep18 06:15 GNW Novartis AG Health 208,186m Launch of Alcon Experience Academy Reinforces Commitment to Training and Education for Eye Care Professionals
13Sep18 06:15 GNW Novartis AG Health 208,186m Novartis real-world evidence confirms efficacy and safety benefits of Cosentyx® in daily life for psoriasis patients
12Sep18 22:00 GNW Novartis AG Health 208,186m Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with MS
12Sep18 06:15 GNW Novartis AG Health 208,186m Novartis survey shows psoriasis patients want treatment effect beyond clear skin
11Sep18 06:00 GNW Novartis AG Health 208,186m Alcon confirms commitment to Switzerland ahead of proposed spinoff from Novartis
06Sep18 03:30 GNW Novartis AG Health 208,186m Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo
29Aug18 06:15 GNW Novartis AG Health 208,186m European Commission approves Novartis combination therapy Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600 mutation-positive melanoma
29Aug18 06:00 GNW Novartis AG Health 208,186m Alcon announces voluntary global market withdrawal of CyPass Micro-Stent for surgical glaucoma
29Aug18 06:00 GNW Novartis AG Health 208,186m Alcon announces voluntary global market withdrawal of CyPass Micro-Stent for surgical glaucoma
27Aug18 06:15 GNW Novartis AG Health 208,186m Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel)
25Aug18 10:00 GNW Novartis AG Health 208,186m Novartis announces new data that show Entresto® (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode
23Aug18 06:15 GNW Novartis AG Health 208,186m SOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutation
23Aug18 06:15 GNW Novartis AG Health 208,186m SOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutation
14Aug18 06:00 GNW Novartis AG Health 208,186m Novartis appoints Dr. Klaus Moosmayer as Chief Ethics Risk and Compliance Officer
14Aug18 06:00 GNW Novartis AG Health 208,186m Novartis appoints Dr. Klaus Moosmayer as Chief Ethics Risk and Compliance Officer
30Jul18 21:30 GNW Novartis AG Health 208,186m Novartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its-kind treatment specifically designed for migraine prevention
27Jul18 13:53 GNW Novartis AG Health 208,186m Sandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab)
27Jul18 13:53 GNW Novartis AG Health 208,186m Sandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab)
27Jul18 13:23 GNW Novartis AG Health 208,186m Novartis combination Tafinlar® + Mekinist® receives positive CHMP opinion for adjuvant treatment of BRAF V600 mutation-positive melanoma
23Jul18 06:15 GNW Novartis AG Health 208,186m Novartis renews drug donation of Egaten® (triclabendazole) until 2022, reaffirming its commitment to the fight against liver fluke
19Jul18 06:15 GNW Novartis AG Health 208,186m Novartis demonstrates commitment to lead immuno-dermatology by in-licensing IL-17C compound for atopic dermatitis
Date / Time Source Company % Chg
29Jan20 06:00 GNW Novartis AG 0.70%
Novartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019
06Jan20 06:00 GNW Novartis AG 0.70%
Novartis completes tender offer for all outstanding shares of The Medicines Company
16Dec19 06:15 GNW Novartis AG 0.70%
Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma
05Dec19 06:00 GNW Novartis AG 0.70%
Novartis tender offer for The Medicines Company commences
24Nov19 20:00 GNW Novartis AG 0.70%
Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death
15Nov19 20:06 GNW Novartis AG 0.70%
New Novartis medicine Adakveo® (crizanlizumab) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease
01Nov19 06:15 GNW Novartis AG 0.70%
Novartis Cosentyx® shows encouraging results versus Humira®* from first-of-its-kind head-to-head trial in psoriatic arthritis
30Oct19 06:00 GNW Novartis AG 0.70%
Novartis announces AVXS-101 intrathecal study update
22Oct19 06:00 GNW Novartis AG 0.70%
Novartis delivered another strong quarter with double digit sales growth and core1 margin expansion; 2019 sales and profit guidance raised; Beovu launched in US
08Oct19 06:15 GNW Novartis AG 0.70%
Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
02Oct19 06:15 GNW Novartis AG 0.70%
Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum
29Sep19 15:30 GNW Novartis AG 0.70%
Novartis Kisqali® delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients
17Sep19 06:15 GNW Novartis AG 0.70%
Novartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis
30Aug19 06:15 GNW Novartis AG 0.70%
Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies
29Jul19 06:00 GNW Novartis AG 0.70%
Novartis provides update on Phase III PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFpEF)
18Jul19 06:00 GNW Novartis AG 0.70%
Novartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increased
01Jul19 16:30 GNW Novartis AG 0.70%
Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio
07Jun19 06:00 GNW Novartis AG 0.70%
Novartis announces new leader of Pharmaceuticals Business Unit
26May19 23:00 GNW Novartis AG 0.70%
FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
24May19 17:41 GNW Novartis AG 0.70%
AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families
24May19 17:32 GNW Novartis AG 0.70%
AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)
08May19 23:20 GNW Novartis AG 0.70%
Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care
24Apr19 06:00 GNW Novartis AG 0.70%
Novartis starts 2019 with strong sales and double digit core[1] operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgraded
26Mar19 23:35 GNW Novartis AG 0.70%
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
22Mar19 06:00 GNW Novartis AG 0.70%
Novartis plans for Alcon spin-off on April 9, 2019
14Mar19 06:15 GNW Novartis AG 0.70%
Novartis announces change in Sandoz leadership
25Feb19 22:55 GNW Novartis AG 0.70%
Novartis issues summary financial information for the Alcon eye care business ahead of shareholder vote on proposed spin-off
30Jan19 15:17 GNW Novartis AG 0.70%
NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2018
30Jan19 06:00 GNW Novartis AG 0.70%
Novartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018
21Dec18 13:53 GNW Novartis AG 0.70%
Novartis successfully completes acquisition of Endocyte
20Dec18 06:00 GNW Novartis AG 0.70%
Novartis announces new CEO of Oncology Business Unit
10Dec18 20:42 GNW Novartis AG 0.70%
Sandoz Inc. and Pear Therapeutics Obtain FDA Clearance for reSET-O(TM) to Treat Opioid Use Disorder
08Dec18 13:00 GNW Novartis AG 0.70%
Novartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease
06Dec18 15:30 GNW Novartis AG 0.70%
Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses
03Dec18 06:15 GNW Novartis AG 0.70%
Novartis announces FDA filing acceptance and Priority Review of AVXS-101, a one-time treatment designed to address the genetic root cause of SMA Type 1
02Dec18 15:15 GNW Novartis AG 0.70%
Real-world data show Novartis drug Revolade® improves outcomes for ITP patients compared to other second-line therapies
01Dec18 19:30 GNW Novartis AG 0.70%
Novartis announces longer-term analyses from pivotal Kymriah® trials that showed durable responses are maintained in patients with advanced blood cancers
01Dec18 15:15 GNW Novartis AG 0.70%
Novartis announces new crizanlizumab (SEG101) data analysis in sickle cell disease, and investment in SENTRY clinical program
29Nov18 06:15 GNW Novartis AG 0.70%
Novartis announces EU approval of Gilenya® for children and adolescents with MS, making it the first and only oral disease-modifying treatment for these patients in Europe
27Nov18 06:15 GNW Novartis AG 0.70%
Sandoz receives eighth European Commission approval for a biosimilar with Ziextenzo® (pegfilgrastim)
27Nov18 06:00 GNW Novartis AG 0.70%
Alcon to highlight its vision, strategy and benefits as a standalone company to investors and analysts in New York and London
23Nov18 06:15 GNW Novartis AG 0.70%
Novartis announces landmark EU approval for one-time gene therapy Luxturna® to restore vision in people with rare inherited retinal disease
20Nov18 13:15 GNW Novartis AG 0.70%
Novartis rises to second place in 2018 Access to Medicine Index
16Nov18 21:30 GNW Novartis AG 0.70%
FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication
16Nov18 13:09 GNW Novartis AG 0.70%
Novartis receives positive CHMP opinion to expand Kisqali® combination therapy to all women with HR+/HER2- locally advanced or metastatic breast cancer
13Nov18 21:29 GNW Novartis AG 0.70%
Alcon files initial Form 20-F registration statement with SEC for proposed spinoff; plans investor days in New York and London
13Nov18 21:28 GNW Novartis AG 0.70%
Alcon files initial Form 20-F registration statement with SEC for proposed spinoff; plans investor days in New York and London
11Nov18 16:45 GNW Novartis AG 0.70%
New Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients
05Nov18 06:00 GNW Novartis AG 0.70%
Novartis R&D update highlights industry leading development pipeline including potential blockbusters and advanced therapy platforms
02Nov18 22:00 GNW Novartis AG 0.70%
Sandoz decides not to pursue US biosimilar rituximab; will focus on robust biosimilar portfolio for unmet access and sustainability needs
02Nov18 21:15 GNW Novartis AG 0.70%
Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology
31Oct18 16:30 GNW Novartis AG 0.70%
Sandoz receives US FDA approval for biosimilar Hyrimoz(TM) (adalimumab-adaz)
29Oct18 06:15 GNW Novartis AG 0.70%
Novartis announces clinical collaboration with Pfizer to advance the treatment of NASH
27Oct18 15:08 GNW Novartis AG 0.70%
Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD
26Oct18 06:15 GNW Novartis AG 0.70%
Novartis receives approval for Cosentyx® label update in Europe to include dosing flexibility in psoriatic arthritis
23Oct18 06:15 GNW Novartis AG 0.70%
Alcon to develop SMART Suite digital health platform for cataract surgery
22Oct18 23:30 GNW Novartis AG 0.70%
Novartis announces Lancet publication of pioneering study in migraine prevention showing efficacy of Aimovig® where other treatments have failed
22Oct18 08:15 GNW Novartis AG 0.70%
Novartis COMBI-AD study of Tafinlar® + Mekinist® continues to demonstrate relapse free survival benefit in patients with BRAF V600-mutant stage III melanoma
20Oct18 15:30 GNW Novartis AG 0.70%
Novartis investigational BYL719 (alpelisib) plus fulvestrant nearly doubles median PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer compared to fulvestrant alone
19Oct18 15:00 GNW Novartis AG 0.70%
Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC
19Oct18 06:15 GNW Novartis AG 0.70%
Novartis announces presentation of new Lutathera® NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden
18Oct18 06:02 GNW Novartis AG 0.70%
Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms
18Oct18 06:02 GNW Novartis AG 0.70%
Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms
18Oct18 06:00 GNW Novartis AG 0.70%
Novartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth
18Oct18 06:00 GNW Novartis AG 0.70%
Novartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth
16Oct18 06:15 GNW Novartis AG 0.70%
Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx® leadership in spondyloarthritis
11Oct18 21:35 GNW Novartis AG 0.70%
Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access
10Oct18 21:30 GNW Novartis AG 0.70%
Novartis announces new data from the first direct head-to-head trial to demonstrate superior efficacy of Gilenya® over Copaxone® in patients with relapsing remitting multiple sclerosis
10Oct18 06:15 GNW Novartis AG 0.70%
Breadth of data at ECTRIMS underpins Novartis' relentless commitment to decoding the science of multiple sclerosis (MS) and decreasing the patient burden
09Oct18 21:30 GNW Novartis AG 0.70%
Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study
08Oct18 06:15 GNW Novartis AG 0.70%
Novartis announces FDA and EMA filing acceptance of siponimod, the first and only drug shown to meaningfully delay disability progression in typical SPMS patients
04Oct18 06:15 GNW Novartis AG 0.70%
Sandoz Healthcare Access Challenge (HACk) returns, seeking digital solutions to local healthcare access challenges
03Oct18 06:15 GNW Novartis AG 0.70%
Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals
22Sep18 13:41 GNW Novartis AG 0.70%
Novartis to file for new Lucentis® (ranibizumab) indication in retinopathy of prematurity (ROP), a rare disease in premature infants that often leads to blindness
22Sep18 13:36 GNW Novartis AG 0.70%
New analysis of Novartis Phase III brolucizumab (RTH258) data reinforces superior reduction of retinal fluid, a key marker of disease activity in nAMD
21Sep18 12:27 GNW Novartis AG 0.70%
Sandoz receives positive CHMP opinion for proposed biosimilar pegfilgrastim
21Sep18 12:25 GNW Novartis AG 0.70%
Novartis receives positive CHMP opinion for Gilenya® for the treatment of children and adolescents with MS, marking a major medical advance for young MS patients in Europe
21Sep18 12:24 GNW Novartis AG 0.70%
Novartis announces positive CHMP opinion for one-time gene therapy Luxturna® to treat children and adults with rare inherited retinal disease
17Sep18 21:30 GNW Novartis AG 0.70%
World's largest Alzheimer's survey reveals most adults believe a cure will be developed in their lifetime
17Sep18 06:15 GNW Novartis AG 0.70%
Launch of Alcon Experience Academy Reinforces Commitment to Training and Education for Eye Care Professionals
13Sep18 06:15 GNW Novartis AG 0.70%
Novartis real-world evidence confirms efficacy and safety benefits of Cosentyx® in daily life for psoriasis patients
12Sep18 22:00 GNW Novartis AG 0.70%
Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with MS
12Sep18 06:15 GNW Novartis AG 0.70%
Novartis survey shows psoriasis patients want treatment effect beyond clear skin
11Sep18 06:00 GNW Novartis AG 0.70%
Alcon confirms commitment to Switzerland ahead of proposed spinoff from Novartis
06Sep18 03:30 GNW Novartis AG 0.70%
Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo
29Aug18 06:15 GNW Novartis AG 0.70%
European Commission approves Novartis combination therapy Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600 mutation-positive melanoma
29Aug18 06:00 GNW Novartis AG 0.70%
Alcon announces voluntary global market withdrawal of CyPass Micro-Stent for surgical glaucoma
29Aug18 06:00 GNW Novartis AG 0.70%
Alcon announces voluntary global market withdrawal of CyPass Micro-Stent for surgical glaucoma
27Aug18 06:15 GNW Novartis AG 0.70%
Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel)
25Aug18 10:00 GNW Novartis AG 0.70%
Novartis announces new data that show Entresto® (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode
23Aug18 06:15 GNW Novartis AG 0.70%
SOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutation
23Aug18 06:15 GNW Novartis AG 0.70%
SOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutation
14Aug18 06:00 GNW Novartis AG 0.70%
Novartis appoints Dr. Klaus Moosmayer as Chief Ethics Risk and Compliance Officer
14Aug18 06:00 GNW Novartis AG 0.70%
Novartis appoints Dr. Klaus Moosmayer as Chief Ethics Risk and Compliance Officer
30Jul18 21:30 GNW Novartis AG 0.70%
Novartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its-kind treatment specifically designed for migraine prevention
27Jul18 13:53 GNW Novartis AG 0.70%
Sandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab)
27Jul18 13:53 GNW Novartis AG 0.70%
Sandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab)
27Jul18 13:23 GNW Novartis AG 0.70%
Novartis combination Tafinlar® + Mekinist® receives positive CHMP opinion for adjuvant treatment of BRAF V600 mutation-positive melanoma
23Jul18 06:15 GNW Novartis AG 0.70%
Novartis renews drug donation of Egaten® (triclabendazole) until 2022, reaffirming its commitment to the fight against liver fluke
19Jul18 06:15 GNW Novartis AG 0.70%
Novartis demonstrates commitment to lead immuno-dermatology by in-licensing IL-17C compound for atopic dermatitis
Date / Time Company % Chg
29Jan20 06:00 Novartis AG 0.70%
Novartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019
06Jan20 06:00 Novartis AG 0.70%
Novartis completes tender offer for all outstanding shares of The Medicines Company
16Dec19 06:15 Novartis AG 0.70%
Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma
05Dec19 06:00 Novartis AG 0.70%
Novartis tender offer for The Medicines Company commences
24Nov19 20:00 Novartis AG 0.70%
Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death
15Nov19 20:06 Novartis AG 0.70%
New Novartis medicine Adakveo® (crizanlizumab) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease
01Nov19 06:15 Novartis AG 0.70%
Novartis Cosentyx® shows encouraging results versus Humira®* from first-of-its-kind head-to-head trial in psoriatic arthritis
30Oct19 06:00 Novartis AG 0.70%
Novartis announces AVXS-101 intrathecal study update
22Oct19 06:00 Novartis AG 0.70%
Novartis delivered another strong quarter with double digit sales growth and core1 margin expansion; 2019 sales and profit guidance raised; Beovu launched in US
08Oct19 06:15 Novartis AG 0.70%
Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
02Oct19 06:15 Novartis AG 0.70%
Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum
29Sep19 15:30 Novartis AG 0.70%
Novartis Kisqali® delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients
17Sep19 06:15 Novartis AG 0.70%
Novartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis
30Aug19 06:15 Novartis AG 0.70%
Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies
29Jul19 06:00 Novartis AG 0.70%
Novartis provides update on Phase III PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFpEF)
18Jul19 06:00 Novartis AG 0.70%
Novartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increased
01Jul19 16:30 Novartis AG 0.70%
Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio
07Jun19 06:00 Novartis AG 0.70%
Novartis announces new leader of Pharmaceuticals Business Unit
26May19 23:00 Novartis AG 0.70%
FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
24May19 17:41 Novartis AG 0.70%
AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families
24May19 17:32 Novartis AG 0.70%
AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)
08May19 23:20 Novartis AG 0.70%
Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care
24Apr19 06:00 Novartis AG 0.70%
Novartis starts 2019 with strong sales and double digit core[1] operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgraded
26Mar19 23:35 Novartis AG 0.70%
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
22Mar19 06:00 Novartis AG 0.70%
Novartis plans for Alcon spin-off on April 9, 2019
14Mar19 06:15 Novartis AG 0.70%
Novartis announces change in Sandoz leadership
25Feb19 22:55 Novartis AG 0.70%
Novartis issues summary financial information for the Alcon eye care business ahead of shareholder vote on proposed spin-off
30Jan19 15:17 Novartis AG 0.70%
NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2018
30Jan19 06:00 Novartis AG 0.70%
Novartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018
21Dec18 13:53 Novartis AG 0.70%
Novartis successfully completes acquisition of Endocyte
20Dec18 06:00 Novartis AG 0.70%
Novartis announces new CEO of Oncology Business Unit
10Dec18 20:42 Novartis AG 0.70%
Sandoz Inc. and Pear Therapeutics Obtain FDA Clearance for reSET-O(TM) to Treat Opioid Use Disorder
08Dec18 13:00 Novartis AG 0.70%
Novartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease
06Dec18 15:30 Novartis AG 0.70%
Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses
03Dec18 06:15 Novartis AG 0.70%
Novartis announces FDA filing acceptance and Priority Review of AVXS-101, a one-time treatment designed to address the genetic root cause of SMA Type 1
02Dec18 15:15 Novartis AG 0.70%
Real-world data show Novartis drug Revolade® improves outcomes for ITP patients compared to other second-line therapies
01Dec18 19:30 Novartis AG 0.70%
Novartis announces longer-term analyses from pivotal Kymriah® trials that showed durable responses are maintained in patients with advanced blood cancers
01Dec18 15:15 Novartis AG 0.70%
Novartis announces new crizanlizumab (SEG101) data analysis in sickle cell disease, and investment in SENTRY clinical program
29Nov18 06:15 Novartis AG 0.70%
Novartis announces EU approval of Gilenya® for children and adolescents with MS, making it the first and only oral disease-modifying treatment for these patients in Europe
27Nov18 06:15 Novartis AG 0.70%
Sandoz receives eighth European Commission approval for a biosimilar with Ziextenzo® (pegfilgrastim)
27Nov18 06:00 Novartis AG 0.70%
Alcon to highlight its vision, strategy and benefits as a standalone company to investors and analysts in New York and London
23Nov18 06:15 Novartis AG 0.70%
Novartis announces landmark EU approval for one-time gene therapy Luxturna® to restore vision in people with rare inherited retinal disease
20Nov18 13:15 Novartis AG 0.70%
Novartis rises to second place in 2018 Access to Medicine Index
16Nov18 21:30 Novartis AG 0.70%
FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication
16Nov18 13:09 Novartis AG 0.70%
Novartis receives positive CHMP opinion to expand Kisqali® combination therapy to all women with HR+/HER2- locally advanced or metastatic breast cancer
13Nov18 21:29 Novartis AG 0.70%
Alcon files initial Form 20-F registration statement with SEC for proposed spinoff; plans investor days in New York and London
13Nov18 21:28 Novartis AG 0.70%
Alcon files initial Form 20-F registration statement with SEC for proposed spinoff; plans investor days in New York and London
11Nov18 16:45 Novartis AG 0.70%
New Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients
05Nov18 06:00 Novartis AG 0.70%
Novartis R&D update highlights industry leading development pipeline including potential blockbusters and advanced therapy platforms
02Nov18 22:00 Novartis AG 0.70%
Sandoz decides not to pursue US biosimilar rituximab; will focus on robust biosimilar portfolio for unmet access and sustainability needs
02Nov18 21:15 Novartis AG 0.70%
Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology
31Oct18 16:30 Novartis AG 0.70%
Sandoz receives US FDA approval for biosimilar Hyrimoz(TM) (adalimumab-adaz)
29Oct18 06:15 Novartis AG 0.70%
Novartis announces clinical collaboration with Pfizer to advance the treatment of NASH
27Oct18 15:08 Novartis AG 0.70%
Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD
26Oct18 06:15 Novartis AG 0.70%
Novartis receives approval for Cosentyx® label update in Europe to include dosing flexibility in psoriatic arthritis
23Oct18 06:15 Novartis AG 0.70%
Alcon to develop SMART Suite digital health platform for cataract surgery
22Oct18 23:30 Novartis AG 0.70%
Novartis announces Lancet publication of pioneering study in migraine prevention showing efficacy of Aimovig® where other treatments have failed
22Oct18 08:15 Novartis AG 0.70%
Novartis COMBI-AD study of Tafinlar® + Mekinist® continues to demonstrate relapse free survival benefit in patients with BRAF V600-mutant stage III melanoma
20Oct18 15:30 Novartis AG 0.70%
Novartis investigational BYL719 (alpelisib) plus fulvestrant nearly doubles median PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer compared to fulvestrant alone
19Oct18 15:00 Novartis AG 0.70%
Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC
19Oct18 06:15 Novartis AG 0.70%
Novartis announces presentation of new Lutathera® NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden
18Oct18 06:02 Novartis AG 0.70%
Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms
18Oct18 06:02 Novartis AG 0.70%
Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms
18Oct18 06:00 Novartis AG 0.70%
Novartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth
18Oct18 06:00 Novartis AG 0.70%
Novartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth
16Oct18 06:15 Novartis AG 0.70%
Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx® leadership in spondyloarthritis
11Oct18 21:35 Novartis AG 0.70%
Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access
10Oct18 21:30 Novartis AG 0.70%
Novartis announces new data from the first direct head-to-head trial to demonstrate superior efficacy of Gilenya® over Copaxone® in patients with relapsing remitting multiple sclerosis
10Oct18 06:15 Novartis AG 0.70%
Breadth of data at ECTRIMS underpins Novartis' relentless commitment to decoding the science of multiple sclerosis (MS) and decreasing the patient burden
09Oct18 21:30 Novartis AG 0.70%
Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study
08Oct18 06:15 Novartis AG 0.70%
Novartis announces FDA and EMA filing acceptance of siponimod, the first and only drug shown to meaningfully delay disability progression in typical SPMS patients
04Oct18 06:15 Novartis AG 0.70%
Sandoz Healthcare Access Challenge (HACk) returns, seeking digital solutions to local healthcare access challenges
03Oct18 06:15 Novartis AG 0.70%
Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals
22Sep18 13:41 Novartis AG 0.70%
Novartis to file for new Lucentis® (ranibizumab) indication in retinopathy of prematurity (ROP), a rare disease in premature infants that often leads to blindness
22Sep18 13:36 Novartis AG 0.70%
New analysis of Novartis Phase III brolucizumab (RTH258) data reinforces superior reduction of retinal fluid, a key marker of disease activity in nAMD
21Sep18 12:27 Novartis AG 0.70%
Sandoz receives positive CHMP opinion for proposed biosimilar pegfilgrastim
21Sep18 12:25 Novartis AG 0.70%
Novartis receives positive CHMP opinion for Gilenya® for the treatment of children and adolescents with MS, marking a major medical advance for young MS patients in Europe
21Sep18 12:24 Novartis AG 0.70%
Novartis announces positive CHMP opinion for one-time gene therapy Luxturna® to treat children and adults with rare inherited retinal disease
17Sep18 21:30 Novartis AG 0.70%
World's largest Alzheimer's survey reveals most adults believe a cure will be developed in their lifetime
17Sep18 06:15 Novartis AG 0.70%
Launch of Alcon Experience Academy Reinforces Commitment to Training and Education for Eye Care Professionals
13Sep18 06:15 Novartis AG 0.70%
Novartis real-world evidence confirms efficacy and safety benefits of Cosentyx® in daily life for psoriasis patients
12Sep18 22:00 Novartis AG 0.70%
Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with MS
12Sep18 06:15 Novartis AG 0.70%
Novartis survey shows psoriasis patients want treatment effect beyond clear skin
11Sep18 06:00 Novartis AG 0.70%
Alcon confirms commitment to Switzerland ahead of proposed spinoff from Novartis
06Sep18 03:30 Novartis AG 0.70%
Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo
29Aug18 06:15 Novartis AG 0.70%
European Commission approves Novartis combination therapy Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600 mutation-positive melanoma
29Aug18 06:00 Novartis AG 0.70%
Alcon announces voluntary global market withdrawal of CyPass Micro-Stent for surgical glaucoma
29Aug18 06:00 Novartis AG 0.70%
Alcon announces voluntary global market withdrawal of CyPass Micro-Stent for surgical glaucoma
27Aug18 06:15 Novartis AG 0.70%
Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel)
25Aug18 10:00 Novartis AG 0.70%
Novartis announces new data that show Entresto® (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode
23Aug18 06:15 Novartis AG 0.70%
SOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutation
23Aug18 06:15 Novartis AG 0.70%
SOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutation
14Aug18 06:00 Novartis AG 0.70%
Novartis appoints Dr. Klaus Moosmayer as Chief Ethics Risk and Compliance Officer
14Aug18 06:00 Novartis AG 0.70%
Novartis appoints Dr. Klaus Moosmayer as Chief Ethics Risk and Compliance Officer
30Jul18 21:30 Novartis AG 0.70%
Novartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its-kind treatment specifically designed for migraine prevention
27Jul18 13:53 Novartis AG 0.70%
Sandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab)
27Jul18 13:53 Novartis AG 0.70%
Sandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab)
27Jul18 13:23 Novartis AG 0.70%
Novartis combination Tafinlar® + Mekinist® receives positive CHMP opinion for adjuvant treatment of BRAF V600 mutation-positive melanoma
23Jul18 06:15 Novartis AG 0.70%
Novartis renews drug donation of Egaten® (triclabendazole) until 2022, reaffirming its commitment to the fight against liver fluke
19Jul18 06:15 Novartis AG 0.70%
Novartis demonstrates commitment to lead immuno-dermatology by in-licensing IL-17C compound for atopic dermatitis